Oak Hill Bio Launches With Pipeline and Senior Leadership From Takeda

New Company Committed to Developing Life-Changing Medicines for Extremely Preterm Infants and Patients Suffering from Rare Autoimmune Diseases Pipeline Includes Two Programs with Phase 2 Proof-of-Concept

Related Keywords

United States ,United Kingdom ,Norman Barton ,Smithkline Beecham ,Daniel Curran ,Hill Bio ,Mark Mchale ,Josh Distler ,Chris Railey ,Glaxosmithkline Plc ,Company Committed To Developing Life ,Division Of Neonatology ,Global Program ,De Shaw Co ,Olive View Medical Center ,Astrazeneca ,Takeda Pharmaceutical Company Limited ,Global Program Leader ,Aslan Pharmaceuticals ,New Company Committed ,Developing Life Changing Medicines ,Extremely Preterm Infants ,Patients Suffering ,Rare Autoimmune ,Includes Two Programs ,Concept Data ,Rare Diseases ,Significant Unmet ,Oak Hill ,Victoria Niklas ,Chief Medical Officer ,Rare Genetics Hematology Therapeutic Area Unit ,Chief Financial Officer ,Oak Hill Bio ,Global Program Lead ,Quantitative Equity ,Athanor Capital ,Global Private Investing ,Chief Operating Officer ,Chief Scientific Officer ,Chief Development Officer ,Nemours Children ,Division Chief ,Medical Director ,View Medical ,Marie Fields ,Investor Relations ,Bridge Communications ,Hill ,Aunches ,Ith ,Pipeline ,Senior ,Leadership ,Rom ,Makeda ,